Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Barlesi

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
ESMO Open|June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†A Zer, M-J Ahn, F Barlesi, et al.
ESMO Open|December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancerO Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) programC Leduc, J P Merlio, B Besse, et al.
ESMO Open|April 23, 2024
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohortJ Remon, E Auclin, L Zubiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trialB Besse, J Mazières, L Ribassin-Majed, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France projectH Blons, J-B Oudart, J-P Merlio, et al.
Revue Des Maladies Respiratoires|May 24, 2007
[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]V Westeel, M P Lebitasy, M Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patientsJ Chen, F Facchinetti, F Braye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†J-L Pujol, A Lavole, E Quoix, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
ESMO Open|June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†A Zer, M-J Ahn, F Barlesi, et al.
ESMO Open|December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancerO Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) programC Leduc, J P Merlio, B Besse, et al.
ESMO Open|April 23, 2024
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohortJ Remon, E Auclin, L Zubiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trialB Besse, J Mazières, L Ribassin-Majed, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France projectH Blons, J-B Oudart, J-P Merlio, et al.
Revue Des Maladies Respiratoires|May 24, 2007
[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]V Westeel, M P Lebitasy, M Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patientsJ Chen, F Facchinetti, F Braye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†J-L Pujol, A Lavole, E Quoix, et al.
Pageof 9